Home>
US Stocks>
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals share price today

(ALNY)

Alnylam Pharmaceuticals share price is $243.25 & ₹20,714.93 as on 25 Dec 2024, 2.30 'hrs' IST

$243.25

▲

0.99

(0.41%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Alnylam Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Alnylam Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Alnylam Pharmaceuticals. Get details on the Indian mutual funds that are investing in Alnylam Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Alnylam Pharmaceuticals's financials.

Alnylam Pharmaceuticals share price movements

Today's Low: $236.92
Today's High: $243.90
$243.25
2.6%
Downside
Day's Volatility :2.86%
Upside
0.26%
52 Weeks Low: $141.98
52 Weeks High: $304.39
$243.25
41.63%
Downside
52 Weeks Volatility :53.36%
Upside
20.09%

Alnylam Pharmaceuticals Returns

Period	Alnylam Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-11.17%	-10.0%	0.0%
6 Months	-1.19%	-5.7%	0.0%
1 Year	26.71%	2.8%	0.0%
3 Years	50.37%	-0.4%	-21.1%

Alnylam Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$242.26
Open	$241.7
Today's High	$243.895
Today's Low	$236.92
Market Capitalization	$31.7B
Today's Volume	$675.4K
52 Week High	$304.39
52 Week Low	$141.975
Revenue TTM	$2.1B
EBITDA	$-132.1M
Earnings Per Share (EPS)	$-2.63
Profit Margin	-15.86%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1500.66%

How to invest in Alnylam Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Alnylam Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Alnylam Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Alnylam Pharmaceuticals or ALNY on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Alnylam Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Alnylam Pharmaceuticals shares which would translate to 0.004 fractional shares of Alnylam Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Alnylam Pharmaceuticals, in just a few clicks!

Returns in Alnylam Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Alnylam Pharmaceuticals investment value today

Current value as on today

₹1,29,622

Returns

₹29,622

(+29.62%)

Returns from Alnylam Pharmaceuticals Stock

₹27,223 (+27.22%)

Dollar Returns

₹2,399 (+2.4%)

Indian investors sentiment towards Alnylam Pharmaceuticals

14%

Period: Sep 25, 2024 to Dec 24, 2024. Change in 30 Days versus previous period

Search volume for Alnylam Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Dec 25, 2024. 14% more investors are searching Alnylam Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Alnylam Pharmaceuticals

Capital World Investors
12.80%
FMR Inc
11.38%
Vanguard Group Inc
9.80%
BlackRock Inc
7.40%
Capital Research Global Investors
4.07%
Wellington Management Company LLP
3.84%

Analyst Recommendation on Alnylam Pharmaceuticals

Buy

70%Buy

29%Hold

0%Sell

Based on 34 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 34 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Alnylam Pharmaceuticals

What analysts predicted

Upside of 22.96%

Current:

$243.25

Target:

$299.11

Insights on Alnylam Pharmaceuticals

Price Movement
In the last 1 year, ALNY stock has moved up by 26.8%
Decreasing Revenue
Alnylam Pharmaceuticals, Inc. has experienced a decline in revenue over the past two quarters. Their revenue decreased from $659.82 million to $500.91 million, resulting in an average decrease of 24.1% per quarter.
Decreasing Net Profit
Alnylam Pharmaceuticals, Inc. has experienced a decline in net profit over the last two quarters. The net profit went from -16.88 million dollars to -111.57 million dollars, representing an average decrease of 560.6% per quarter. This indicates significant financial challenges for the company.

Alnylam Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$74.9M	↓ 16.69%
Net Income	$-761.5M	↑ 55.13%
Net Profit Margin	-1.0K%	↓ 470.63%

	FY19	Y/Y Change
Revenue	$219.8M	↑ 193.36%
Net Income	$-886.1M	↑ 16.37%
Net Profit Margin	-403.24%	↑ 613.34%

	FY20	Y/Y Change
Revenue	$492.9M	↑ 124.28%
Net Income	$-858.3M	↓ 3.14%
Net Profit Margin	-174.15%	↑ 229.09%

	FY21	Y/Y Change
Revenue	$844.3M	↑ 71.31%
Net Income	$-852.8M	↓ 0.64%
Net Profit Margin	-101.01%	↑ 73.14%

	FY22	Y/Y Change
Revenue	$1.0B	↑ 22.88%
Net Income	$-1.1B	↑ 32.64%
Net Profit Margin	-109.04%	↓ 8.03%

	FY23	Y/Y Change
Revenue	$1.8B	↑ 76.23%
Net Income	$-440.2M	↓ 61.08%
Net Profit Margin	-24.08%	↑ 84.96%

	Q2 FY23	Q/Q Change
Revenue	$318.8M	↓ 0.17%
Net Income	$-276.0M	↑ 58.54%
Net Profit Margin	-86.59%	↓ 32.06%

	Q3 FY23	Q/Q Change
Revenue	$750.5M	↑ 135.46%
Net Income	$147.8M	↓ 153.53%
Net Profit Margin	19.69%	↑ 106.28%

	Q4 FY23	Q/Q Change
Revenue	$439.7M	↓ 41.41%
Net Income	$-137.9M	↓ 193.31%
Net Profit Margin	-31.35%	↓ 51.04%

	Q1 FY24	Q/Q Change
Revenue	$494.3M	↑ 12.42%
Net Income	$-65.9M	↓ 52.18%
Net Profit Margin	-13.34%	↑ 18.01%

	Q2 FY24	Q/Q Change
Revenue	$659.8M	↑ 33.48%
Net Income	$-16.9M	↓ 74.39%
Net Profit Margin	-2.56%	↑ 10.78%

	Q3 FY24	Q/Q Change
Revenue	$500.9M	↓ 24.08%
Net Income	$-111.6M	↑ 560.61%
Net Profit Margin	-22.27%	↓ 19.71%

	FY18	Y/Y Change
Profit	$73.1M	↓ 18.69%

	FY19	Y/Y Change
Profit	$194.7M	↑ 166.31%

	FY20	Y/Y Change
Profit	$414.8M	↑ 113.06%

	FY21	Y/Y Change
Profit	$704.1M	↑ 69.75%

	FY22	Y/Y Change
Profit	$868.6M	↑ 23.36%

	FY23	Y/Y Change
Profit	$1.5B	↑ 74.75%

	Q2 FY23	Q/Q Change
Profit	$233.4M	↓ 11.74%

	Q3 FY23	Q/Q Change
Profit	$666.2M	↑ 185.46%

	Q4 FY23	Q/Q Change
Profit	$353.9M	↓ 46.89%

	Q1 FY24	Q/Q Change
Profit	$428.4M	↑ 21.05%

	Q2 FY24	Q/Q Change
Profit	$591.2M	↑ 38.0%

	Q3 FY24	Q/Q Change
Profit	$415.0M	↓ 29.8%

	FY18	Y/Y Change
Operating Cash Flow	$-562.6M	↑ 46.98%
Investing Cash Flow	$272.9M	↓ 194.0%
Financing Cash Flow	$65.5M	↓ 94.18%

	FY19	Y/Y Change
Operating Cash Flow	$-278.4M	↓ 50.51%
Investing Cash Flow	$-417.7M	↓ 253.03%
Financing Cash Flow	$823.2M	↑ 1157.35%

	FY20	Y/Y Change
Operating Cash Flow	$-615.0M	↑ 120.87%
Investing Cash Flow	$-435.5M	↑ 4.27%
Financing Cash Flow	$995.0M	↑ 20.87%

	FY21	Y/Y Change
Operating Cash Flow	$-641.7M	↑ 4.35%
Investing Cash Flow	$-273.3M	↓ 37.25%
Financing Cash Flow	$1.2B	↑ 25.34%

	FY22	Y/Y Change
Operating Cash Flow	$-541.3M	↓ 15.65%
Investing Cash Flow	$169.4M	↓ 161.97%
Financing Cash Flow	$425.8M	↓ 65.86%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-59.0M	↓ 64.57%
Investing Cash Flow	$-8.7M	↓ 88.57%
Financing Cash Flow	$53.4M	↑ 15.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$359.4M	↓ 709.32%
Investing Cash Flow	$-10.8M	↑ 23.54%
Financing Cash Flow	$33.1M	↓ 37.94%

Alnylam Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Alnylam Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Alnylam Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Alnylam Pharmaceuticals, Inc.	-3.47%	-1.19%	26.71%	50.37%	106.11%
Regeneron Pharmaceuticals, Inc.	-4.59%	-33.11%	-15.82%	12.66%	91.56%
Biontech Se	-6.0%	37.55%	8.38%	-55.46%	248.4%
Vertex Pharmaceuticals Incorporated	-12.22%	-14.5%	-0.59%	82.27%	83.4%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Regeneron Pharmaceuticals, Inc.	17.36	17.36	1.04	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Vertex Pharmaceuticals Incorporated	32.84	NA	1.04	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Alnylam Pharmaceuticals, Inc.	Buy	$31.7B	106.11%	NA	-15.86%
Regeneron Pharmaceuticals, Inc.	Buy	$77.1B	91.56%	17.36	33.61%
Biontech Se	Buy	$27.1B	248.4%	160.8	-15.36%
Vertex Pharmaceuticals Incorporated	Buy	$102.3B	83.4%	32.84	-4.51%

Alnylam Pharmaceuticals Dividend announcements

Alnylam Pharmaceuticals Earnings
Alnylam Pharmaceuticals’s price-to-earnings ratio stands at None
Read More

About Alnylam Pharmaceuticals

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Organization	Alnylam Pharmaceuticals
Employees	2100
CEO	Dr. Yvonne L. Greenstreet M.B.A., MBChB
Industry	Health Technology

Management People of Alnylam Pharmaceuticals

Name	Title
Dr. Yvonne L. Greenstreet M.B.A., MBChB	CEO & Director
Mr. Jeffrey V. Poulton M.B.A.	CFO & Executive VP
Dr. Akshay K. Vaishnaw M.D., Ph.D.	Chief Innovation Officer & Member of the Scientific Advisory Board
Dr. Pushkal P. Garg M.D.	Chief Medical Officer
Mr. Tolga Tanguler M.B.A.	Executive VP & Chief Commercial Officer
Mr. Timothy J. Maines	Chief Technical Operations & Quality Officer
Dr. Kevin Joseph Fitzgerald Ph.D.	Senior VP, Head of Research & Chief Scientific Officer
Mr. Piyush Sharma J.D.	Chief Ethics & Compliance Officer
Mr. Robert W. Hesslein Esq., J.D.	Chief Legal Officer & Corporate Secretary
Ms. Christine Regan Lindenboom	Chief Corporate Communications Officer

Important FAQs about investing in Alnylam Pharmaceuticals from India :

What is Alnylam Pharmaceuticals share price today?

Alnylam Pharmaceuticals share price today stands at $243.25, Open: $241.70 ; Previous Close: $242.26 ; High: $243.90 ; Low: $236.92 ; 52 Week High: $304.39 ; 52 Week Low: $141.98. The stock opens at $241.70, after a previous close of $242.26. The stock reached a daily high of $243.90 and a low of $236.92, with a 52-week high of $304.39 and a 52-week low of $141.98.

Can Indians buy Alnylam Pharmaceuticals shares?

Yes, Indians can invest in the Alnylam Pharmaceuticals (ALNY) from India.

With INDmoney, you can buy Alnylam Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Alnylam Pharmaceuticals at zero transaction cost.

How can I buy Alnylam Pharmaceuticals shares from India?

It is very easy to buy Alnylam Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Alnylam Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Alnylam Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Alnylam Pharmaceuticals stocks?

To start investing in Alnylam Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.